Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1057-1062.doi: 10.35541/cjd.20210568
• Guidelines and Consensus • Previous Articles Next Articles
Centre for Urticaria Research, Chinese Society of Dermatology
Received:
2021-08-06
Revised:
2021-09-26
Online:
2021-12-15
Published:
2021-12-01
Contact:
Xu Jinhua
E-mail:xjhhsyy@163.com
Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab)[J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062.doi:10.35541/cjd.20210568
[1] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1): 1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[2] | Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update[J]. J Allergy Clin Immunol, 2014,133(5):1270⁃1277. doi: 10.1016/j.jaci.2014.02.036. |
[3] | Ulambayar B, Park HS. Anti⁃TPO IgE autoantibody in chronic urticaria: is it clinically relevant?[J]. Allergy Asthma Immunol Res, 2019,11(1):1⁃3. doi: 10.4168/aair.2019.11.1.1. |
[4] | Kaplan AP, Giménez⁃Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria[J]. Allergy, 2017,72(4):519⁃533. doi: 10.1111/all.13 083. |
[5] | Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin[J]. Theranostics, 2017,7(5):1266⁃1276. doi: 10.7150/thno.18304. |
[6] | Serrano⁃Candelas E, Martinez⁃Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils[J]. Clin Exp Allergy, 2016,46(1):92⁃102. doi: 10.1111/cea. 12668. |
[7] | Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells[J]. Clin Transl Allergy, 2013,3(1):29. doi: 10.1186/2045⁃7022⁃3⁃29. |
[8] | Sánchez⁃Machín I, Iglesias⁃Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab[J]. Clin Mol Allergy, 2011,9:11. doi: 10.1186/1476⁃7961⁃9⁃11. |
[9] | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
[10] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa121 5372. |
[11] | Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306. |
[12] | Novartis Pharmaceuticals. Study of efficacy and safety of Xolair® (Omalizumab) in Chinese patients with chronic spontaneous urticaria[DB/OL]. (2020⁃11⁃04)[2021⁃10⁃08]. https://clinicaltrials.gov/ct2/show/NCT03328897. |
[13] | 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021,54(7):582⁃585. doi: 10.35541/cjd.20201261. |
[14] | Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043. |
[15] | Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042. |
[16] | Gastaminza G, Azofra J, Nunez⁃Cordoba JM, et al. Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double⁃blind and open⁃label placebo⁃controlled clinical trial[J]. J Allergy Clin Immunol Pract, 2019,7(5):1599⁃1609.e1. doi: 10.1016/j.jaip.2018.12.025. |
[17] | Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032. |
[18] | Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2015,115(2):126⁃129. doi: 10.1016/j.anai. 2015.05.010. |
[19] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[20] | Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence⁃based practice guidelines for chronic spontaneous urticaria in Korean adults and children: Part 2. Management of H1⁃antihistamine⁃refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2020,12(5):750⁃770. doi: 10.4168/aair.2020.12. 5.750. |
[21] | Cox L, Platts⁃Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/american College of Allergy, Asthma And Immunology Joint Task Force Report on omalizumab⁃associated anaphylaxis[J]. J Allergy Clin Immunol, 2007,120(6):1373⁃1377. doi: 10.1016/j.jaci.2007.09.032. |
[22] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[23] | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091. |
[24] | Curto⁃Barredo L, Spertino J, Figueras⁃Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria[J]. Br J Dermatol, 2018,179(1):210⁃212. doi: 10.1111/bjd.16379. |
[25] | Serarslan G, Uzun M, Doğramacı AÇ, et al. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study[J]. Dermatol Ther, 2019,32(1):e12752. doi: 10.1111/dth.12752. |
[26] | Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345. |
[27] | Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350. |
[28] | Ferrer M, Boccon⁃Gibod I, Gonçalo M, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria[J]. Eur J Dermatol, 2017,27(5):455⁃463. doi: 10.1684/ejd.2017.3085. |
[29] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[30] | Pinto Gouveia M, Gameiro A, Pinho A, et al. Long⁃term management of chronic spontaneous urticaria with omalizumab[J]. Clin Exp Dermatol, 2017,42(7):735⁃742. doi: 10.1111/ced. 13173. |
[31] | Alizadeh Aghdam M, Pieterse RH, Kentie PA, et al. Effective omalizumab interval prolongation in the treatment of chronic urticaria[J]. J Allergy Clin Immunol Pract, 2020,8(10):3667⁃3668.e1. doi: 10.1016/j.jaip.2020.06.056. |
[32] | Kavati A, Zhdanava M, Ortiz B, et al. Long⁃term omalizumab outcomes in chronic idiopathic urticaria: a real⁃world study[J]. Allergy Asthma Proc, 2019,40(5):321⁃328. doi: 10.2500/aap. 2019.40.4236. |
[33] | Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ′real⁃world′ evidence[J]. Expert Opin Biol Ther, 2018,18(4):425⁃448. doi: 10.1080/14712598.2018.1438406. |
[34] | 奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018,41(3):179⁃185. doi: 10.3760/cma.j.issn.1001⁃0939.2018.03.007. |
[35] | Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies[J]. Case Rep Med, 2015,2015:368053. doi: 10.1155/2015/368053. |
[36] | Ben⁃Shoshan M, Grattan CE. Management of pediatric urticaria with review of the literature on chronic spontaneous urticaria in children[J]. J Allergy Clin Immunol Pract, 2018,6(4):1152⁃1161. doi: 10.1016/j.jaip.2018.02.015. |
[37] | Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers[J]. J Allergy Clin Immunol Pract, 2020,8(1):113⁃124. doi: 10.1016/j.jaip.2019.07.021. |
[38] | Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real⁃life experience[J]. Ann Allergy Asthma Immunol, 2018,120(3):318⁃323. doi: 10.1016/j.anai.2017.12.007. |
[39] | Agache I, Akdis C, Akdis M, et al. EAACI Biologicals Guidelines⁃Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12⁃17 years old[J/OL]. Allergy, 2021 (2021⁃07⁃29) [2021⁃10⁃08]. https://onlinelibrary.wiley.com/doi/10.1111/all.15030. doi: 10. 1111/ all.15030. [published online ahead of print]. |
[40] | Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real⁃life data from a multicenter observational study focusing on elderly patients[J]. Dermatol Ther, 2021,34(2):e14841. doi: 10.1111/dth.14841. |
[41] | Bauer A, Dickel H, Jakob T, et al. Expert consensus on practical aspects in the treatment of chronic urticaria[J]. Allergo J Int, 2021,30(2):64⁃75. doi: 10.1007/s40629⁃021⁃00162⁃w. |
[42] | Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria[J]. N Engl J Med, 2019,381(14):1321⁃1332. doi: 10.1056/NEJMoa1900408. |
[43] | Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2016, 138(6):1730⁃1732. doi: 10.1016/j.jaci.2016.06.023. |
[1] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[2] | Wang Juanjuan, Chen Rong, Ji Jiang, Su Wenxing, Wei Yuqian, Zhao Ying, Yin Xingping, Su Yuhua, Shi Xin. Retrospective analysis of 67 cases of neurosyphilis with abnormal mental behaviors as the initial symptom [J]. Chinese Journal of Dermatology, 2022, 55(3): 231-234. |
[3] | Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263. |
[4] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[5] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
[6] | Wang Jiaqi, Wang Ping, Li Liuyu, Fan Qimin, Zhu Mengyan, Wang Yanqing, Zhou Hongyu, Shen Hong, Xu Ai′e. Cutaneous hypopigmented lymphoproliferative disorders: a clinicopathological study of 41 cases [J]. Chinese Journal of Dermatology, 2022, 55(2): 110-115. |
[7] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
[8] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
[9] | Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64. |
[10] | Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75. |
[11] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420. |
[12] | Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784. |
[13] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
[14] | Zhang Yu, Gao Yingxia, Gu Ningyan, Zhu Hong, Chen Jingjing, Hu Qingjie, Zhou Min, Duan Yuanyuan, Yao Xu. Clinical efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2021, 54(7): 582-585. |
[15] | Liang Gaopeng, Song Zhiqiang. Role of immunoglobulin E autoantibodies in autoimmune skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(6): 553-556. |
|